Josie Tirzepatide Review

Josie treats GLP-1 therapy as one option within midlife women's health rather than as the whole product, which is a more clinically coherent framing than most of this category manages. Our research (September 1, 2026) found careful disclosure language and one product line we would question.

The Clinical Framing Is Right for the Population

"Provider-led telehealth for women in perimenopause and menopause. Licensed providers review your intake and may discuss HRT, GLP-1, or microdose maintenance care when appropriate."

Weight change in perimenopause is entangled with hormonal change, and a service that can consider hormone therapy and GLP-1 therapy together — rather than selling one regardless of which is indicated — is better positioned than a single-product operator. Josie states that a provider decides which path applies:

"A licensed Josie provider reviews your intake to determine whether HRT, full-dose GLP-1, or microdose maintenance care may be appropriate."

Care is supervised by Dr. Ana Lisa Carr, MD, with providers described as licensed physicians and nurse practitioners specialising in women's health and midlife care, each licensed in the patient's own state. The service operates in all 50 states, with most patients hearing from a provider within 24 to 48 hours.

The Compounding Disclosures Are Unusually Scrupulous

"Compounded GLP-1 medications are not FDA-approved, and the FDA does not review compounded medications for safety, effectiveness, or quality before marketing. A licensed Josie provider will review your intake to determine whether GLP-1 care may be appropriate."

And a detail almost nobody publishes:

"Josie does not manufacture compounded medications. Actual product appearance and labeling of the medication you receive will differ from website images."

Telling patients the vial will not look like the marketing photograph is a small thing that prevents a real confusion — patients who receive an unfamiliar-looking product and wonder whether it is legitimate. Josie also attaches its disclaimer to its own savings estimator, stating the estimate "is not a medical recommendation, a guarantee, or a promise of outcome." The post-shortage caveat applies as everywhere: with the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding depends on a documented clinical reason for the individual patient.

Pricing

Weight Management (GLP-1 provider-led care): as low as $194/month. HRT: as low as $89/month. Weight Maintenance (microdose longevity protocol): $189/month. The entry quiz advertises up to $100 off, takes about a minute and requires no email address — a low-friction, low-pressure entry that does not harvest contact details before showing anything. Josie does not accept insurance and describes its pricing as transparent. The figures are "as low as," and no dose-tier table is published showing what a therapeutic dose costs, which is the main pricing gap.

The Microdose Protocol Is the Thing to Question

Josie sells "Weight Maintenance — microdose longevity protocol" at $189/month as a distinct care path. Microdosing GLP-1 receptor agonists is not an approved protocol and is not supported by the registrational trial evidence that established these drugs' efficacy and safety; framing it additionally as a "longevity" intervention extends it further, into a use with no controlled outcome evidence in humans at all. Note also that at $189 it is priced just below the $194 full-dose GLP-1 path — so the less-evidenced option is marginally the cheaper one. That is a smaller gap than we have criticised elsewhere, but the direction is the same. If a Josie provider proposes microdose maintenance, that may well be a defensible individualised decision after a course of full-dose therapy. Sold as a catalogue tier, it is something to ask about rather than assume.

What Is Not Published

No named pharmacy and no 503A/503B status — only "a licensed pharmacy or compounding pharmacy." No BMI or clinical eligibility criteria; eligibility is stated to be determined by a provider during clinical review, which is correct but leaves the standard unstated. No lab requirements, no dose-tier pricing, no titration protocol, no monitoring cadence, no founding year, and no refund or cancellation terms.